BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 34935436)

  • 1. Emerging Chikungunya Virus Variants at the E1-E1 Interglycoprotein Spike Interface Impact Virus Attachment and Inflammation.
    Rangel MV; McAllister N; Dancel-Manning K; Noval MG; Silva LA; Stapleford KA
    J Virol; 2022 Feb; 96(4):e0158621. PubMed ID: 34935436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chikungunya Virus Fidelity Variants Exhibit Differential Attenuation and Population Diversity in Cell Culture and Adult Mice.
    Riemersma KK; Steiner C; Singapuri A; Coffey LL
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.
    Pal P; Fox JM; Hawman DW; Huang YJ; Messaoudi I; Kreklywich C; Denton M; Legasse AW; Smith PP; Johnson S; Axthelm MK; Vanlandingham DL; Streblow DN; Higgs S; Morrison TE; Diamond MS
    J Virol; 2014 Aug; 88(15):8213-26. PubMed ID: 24829346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-amino-acid polymorphism in Chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization.
    Silva LA; Khomandiak S; Ashbrook AW; Weller R; Heise MT; Morrison TE; Dermody TS
    J Virol; 2014 Mar; 88(5):2385-97. PubMed ID: 24371059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
    Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two Conserved Phenylalanine Residues in the E1 Fusion Loop of Alphaviruses Are Essential for Viral Infectivity.
    Lucas CJ; Davenport BJ; Carpentier KS; Tinega AN; Morrison TE
    J Virol; 2022 May; 96(9):e0006422. PubMed ID: 35416719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.
    Fong RH; Banik SS; Mattia K; Barnes T; Tucker D; Liss N; Lu K; Selvarajah S; Srinivasan S; Mabila M; Miller A; Muench MO; Michault A; Rucker JB; Paes C; Simmons G; Kahle KM; Doranz BJ
    J Virol; 2014 Dec; 88(24):14364-79. PubMed ID: 25275138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of the Opal Stop Codon Attenuates Chikungunya Virus-Induced Arthritis and Pathology.
    Jones JE; Long KM; Whitmore AC; Sanders W; Thurlow LR; Brown JA; Morrison CR; Vincent H; Peck KM; Browning C; Moorman N; Lim JK; Heise MT
    mBio; 2017 Nov; 8(6):. PubMed ID: 29138302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residue 82 of the Chikungunya virus E2 attachment protein modulates viral dissemination and arthritis in mice.
    Ashbrook AW; Burrack KS; Silva LA; Montgomery SA; Heise MT; Morrison TE; Dermody TS
    J Virol; 2014 Nov; 88(21):12180-92. PubMed ID: 25142598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chikungunya Virus Strains from Each Genetic Clade Bind Sulfated Glycosaminoglycans as Attachment Factors.
    McAllister N; Liu Y; Silva LM; Lentscher AJ; Chai W; Wu N; Griswold KA; Raghunathan K; Vang L; Alexander J; Warfield KL; Diamond MS; Feizi T; Silva LA; Dermody TS
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting the Role of E2 Protein Domains in Alphavirus Pathogenicity.
    Weger-Lucarelli J; Aliota MT; Wlodarchak N; Kamlangdee A; Swanson R; Osorio JE
    J Virol; 2015 Dec; 90(5):2418-33. PubMed ID: 26676771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the chikungunya virus E1 glycoprotein domain II and hinge influence E2 conformation, infectivity, and virus-receptor interactions.
    Thannickal SA; Battini L; Spector SN; Noval MG; Álvarez DE; Stapleford KA
    J Virol; 2024 Jun; ():e0067924. PubMed ID: 38842335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chikungunya Virus Replication Rate Determines the Capacity of Crossing Tissue Barriers in Mosquitoes.
    Merwaiss F; Filomatori CV; Susuki Y; Bardossy ES; Alvarez DE; Saleh MC
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33148794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Molecular Surveillance of Chikungunya Virus.
    Fischer C; de Lamballerie X; Drexler JF
    mSphere; 2019 Jul; 4(4):. PubMed ID: 31270168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host oxidative folding pathways offer novel anti-chikungunya virus drug targets with broad spectrum potential.
    Langsjoen RM; Auguste AJ; Rossi SL; Roundy CM; Penate HN; Kastis M; Schnizlein MK; Le KC; Haller SL; Chen R; Watowich SJ; Weaver SC
    Antiviral Res; 2017 Jul; 143():246-251. PubMed ID: 28461071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chikungunya Virus' High Genomic Plasticity Enables Rapid Adaptation to Restrictive A549 Cells.
    De Caluwé L; Heyndrickx L; Coppens S; Vereecken K; Quiñones-Mateu ME; Merits A; Ariën KK; Bartholomeeusen K
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suramin Inhibits Chikungunya Virus Replication by Interacting with Virions and Blocking the Early Steps of Infection.
    Albulescu IC; White-Scholten L; Tas A; Hoornweg TE; Ferla S; Kovacikova K; Smit JM; Brancale A; Snijder EJ; van Hemert MJ
    Viruses; 2020 Mar; 12(3):. PubMed ID: 32191995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design.
    Gardner CL; Hritz J; Sun C; Vanlandingham DL; Song TY; Ghedin E; Higgs S; Klimstra WB; Ryman KD
    PLoS Negl Trop Dis; 2014 Feb; 8(2):e2719. PubMed ID: 24587470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The chikungunya virus E1 glycoprotein fusion loop and hinge alter glycoprotein dynamics leading to cell and host specific changes in infectivity.
    Thannickal SA; Battini L; Spector SN; Noval MG; Álvarez DE; Stapleford KA
    bioRxiv; 2023 Nov; ():. PubMed ID: 37961096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential adaptive mutations enhance efficient vector switching by Chikungunya virus and its epidemic emergence.
    Tsetsarkin KA; Weaver SC
    PLoS Pathog; 2011 Dec; 7(12):e1002412. PubMed ID: 22174678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.